These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31227810)

  • 41. Beyond vertical and horizontal programs: a diagonal approach to building national immunization programs through measles elimination.
    Orenstein WA; Seib K
    Expert Rev Vaccines; 2016 Jul; 15(7):791-3. PubMed ID: 26967373
    [No Abstract]   [Full Text] [Related]  

  • 42. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measles vaccination effectiveness among children under 5 years of age in Kampala, Uganda.
    Mupere E; Karamagi C; Zirembuzi G; Grabowsky M; de Swart RL; Nanyunja M; Mayanja H
    Vaccine; 2006 May; 24(19):4111-5. PubMed ID: 16554111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atypical measles in a patient twice vaccinated against measles: transmission from an unvaccinated household contact.
    Artimos de Oliveira S; Jin L; Siqueira MM; Cohen BJ
    Vaccine; 2000 Dec; 19(9-10):1093-6. PubMed ID: 11137243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The declining antibody level of measles virus in China population, 2009-2015.
    Hu Y; Lu P; Deng X; Guo H; Zhou M
    BMC Public Health; 2018 Jul; 18(1):906. PubMed ID: 30041607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity.
    Mossong J; Nokes DJ; Edmunds WJ; Cox MJ; Ratnam S; Muller CP
    Am J Epidemiol; 1999 Dec; 150(11):1238-49. PubMed ID: 10588085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improving MMR vaccination rates: herd immunity is a realistic goal.
    Cockman P; Dawson L; Mathur R; Hull S
    BMJ; 2011 Oct; 343():d5703. PubMed ID: 21971162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies.
    Hennessey KA; Ion-Nedelcu N; Craciun MD; Toma F; Wattigney W; Strebel PM
    Am J Epidemiol; 1999 Dec; 150(11):1250-7. PubMed ID: 10588086
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monkeypox as a warning to preserve global herd immunities.
    Miranda D; Sanchez DJ
    Virulence; 2023 Dec; 14(1):2154424. PubMed ID: 36602152
    [No Abstract]   [Full Text] [Related]  

  • 50. New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population.
    Plans P
    Eur J Clin Microbiol Infect Dis; 2013 Jul; 32(7):961-6. PubMed ID: 23417624
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measles in the United States, 2006.
    Mulholland EK
    N Engl J Med; 2006 Aug; 355(5):440-3. PubMed ID: 16885546
    [No Abstract]   [Full Text] [Related]  

  • 52. Waning immunity and subclinical measles infections in England.
    Glass K; Grenfell BT
    Vaccine; 2004 Sep; 22(29-30):4110-6. PubMed ID: 15364464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An increasing, potentially measles-susceptible population over time after vaccination in Korea.
    Kang HJ; Han YW; Kim SJ; Kim YJ; Kim AR; Kim JA; Jung HD; Eom HE; Park O; Kim SS
    Vaccine; 2017 Jul; 35(33):4126-4132. PubMed ID: 28669617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Measles and the importance of maintaining vaccination levels.
    Bedford H
    Nurs Times; 2004 Jun 29-Jul 6; 100(26):52-5. PubMed ID: 15318694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Possibilities of measles vaccination in children with counterindications and duration of preservation of postvaccinal immunity].
    Piriev GG; Liashchenko VA
    Pediatriia; 1990; (12):27-30. PubMed ID: 2075059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
    [No Abstract]   [Full Text] [Related]  

  • 58. Measles immunity and vaccination policy in Catalonia.
    Domínguez A; Vidal J; Plans P; Carmona G; Godoy P; Batalla J; Salleras L
    Vaccine; 1999 Feb; 17(6):530-4. PubMed ID: 10075158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Public health response to a measles outbreak in a large correctional facility, Queensland, 2013.
    Chatterji M; Baldwin AM; Prakash R; Vlack SA; Lambert SB
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E294-7. PubMed ID: 25631590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Immunological reactivity of children vaccinated with a live measles vaccine].
    Bolotovskiĭ VM; Titova NS; Zakharova TR; Vorotyntseva NV; Mushkova EM
    Vopr Virusol; 1983; 28(5):588-90. PubMed ID: 6659474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.